For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. If you need to see your provider, please contact us to see if a Video Visit is right for you. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Department of Anesthesiology

You are here

Gabapentin adjunctive therapy in neuropathic pain states.

TitleGabapentin adjunctive therapy in neuropathic pain states.
Publication TypeJournal Article
Year of Publication1996
AuthorsRosner H, Rubin L, Kestenbaum A
JournalClin J Pain
Date Published1996 Mar
KeywordsAcetates, Adult, Aged, Amines, Analgesics, Cyclohexanecarboxylic Acids, Facial Pain, Female, gamma-Aminobutyric Acid, Herpesviridae Infections, HIV Infections, Humans, Intervertebral Disc Displacement, Male, Middle Aged, Neuralgia, Pain, Intractable, Peripheral Nervous System Diseases

OBJECTIVE: This is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain.

DESIGN: A case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects.

SETTING: An outpatient pain management center located within a major university medical center.

PATIENTS: Convenience sample of patients referred for management of intractable neuropathic pain.

INTERVENTIONS: Simplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses.

MAIN OUTCOME MEASURES: Patient self-reports and pain scores in successive office visits.

RESULTS: Gabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.

Alternate JournalClin J Pain
PubMed ID8722736